XML 22 R11.htm IDEA: XBRL DOCUMENT
v3.22.1

NIH Contract | 3 Months Ended
--- | ---
Mar. 31, 2022
Research and Development [Abstract] |
NIH Contract | NIH ContractIn 2020, we were awarded the NIH Contract under the RADx program to support the expansion of our production capacity and throughput capabilities for COVID-19 testing with our microfluidics technology. We completed the required milestones in 2021 and received the total NIH Contract value of $34.0 million. Proceeds from the NIH Contract have been used primarily for capital expenditures to expand production capacity and, to a lesser extent, to offset applicable operating costs. Grant proceeds that exceed the cost of the capital expenditures and expenses that have been and are expected to be incurred are recorded in other non-operating income. The following table summarizes the activity under the NIH Contract as of March 31, 2022 and December 31, 2021 (in thousands):
|  | March 31, 2022 |  | December 31, 2021
Cash receipts from milestones achieved |  | $ | 34,016 |  |  | $ | 34,016 |
Cumulative amounts applied against operating costs (excluding depreciation) |  | (4,526) |  |  | (4,522) |
Cumulative amounts applied against depreciation expense for assets placed in service |  | (1,510) |  |  | (703) |
Cumulative amounts recognized as non-operating income |  | (7,140) |  |  | (7,140) |
Total deferred grant income |  | $ | 20,840 |  |  | $ | 21,651 |
Assets placed in service, gross |  | $ | 20,425 |  |  | $ | 16,890 |
Construction-in-progress |  | 937 |  |  | 3,909 |
Cumulative amounts applied against depreciation expense |  | (1,510) |  |  | (703) |
Carrying value of property and equipment, net |  | 19,852 |  | 20,096
Estimated future capital expenditures |  | 988 |  |  | 1,555 |
Total deferred grant income |  | $ | 20,840 |  |  | $ | 21,651 |
Deferred grant income, current |  | $ | 3,603 |  |  | $ | 3,535 |
Deferred grant income, non-current |  | 17,237 |  |  | 18,116 |
Total deferred grant income |  | $ | 20,840 |  |  | $ | 21,651 |
Deferred grant income, current on the condensed consolidated balance sheet represents amounts expected to be offset against depreciation expense over the next twelve months. Deferred grant income, non-current includes amounts expected to be offset against depreciation expense in later periods. We expect to spend $22.4 million on capital expenditures associated with the NIH Contract. We have incurred $21.4 million of capital expenditures th rough March 31, 2022, of which $20.4 million has been placed in service, while the remaining $0.9 million is included in construction-in-progress (See Note 8). We expect to place the remaining equipment in service by the end of the first half of 2022.

X
- References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 730 -URI http://asc.fasb.org/subtopic&trid=2197926 + Details
Name: | us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration